Atezolizumab and bevacizumab: the revolutionary duo as a game changer in advanced hepatocellular carcinoma.
作者信息
Zhang D X
机构信息
Department of Biomedical Sciences, City University of Hong Kong, Kowloon, Hong Kong SAR.
Department of Molecular Biology and Genetics, Cornell University, Ithaca, USA.
出版信息
Immunooncol Technol. 2020 Jun 25;7:1. doi: 10.1016/j.iotech.2020.06.002. eCollection 2020 Sep.
Abstract
摘要
相似文献
1
Atezolizumab and bevacizumab: the revolutionary duo as a game changer in advanced hepatocellular carcinoma.阿替利珠单抗和贝伐珠单抗：这一革命性组合成为晚期肝细胞癌治疗的变革者。
Immunooncol Technol. 2020 Jun 25;7:1. doi: 10.1016/j.iotech.2020.06.002. eCollection 2020 Sep.
2
Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.经动脉放射性栓塞与阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌：生活质量恶化时间的匹配调整间接比较。
Adv Ther. 2022 May;39(5):2035-2051. doi: 10.1007/s12325-022-02099-0. Epub 2022 Mar 12.
3
Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports.阿特珠单抗和贝伐单抗治疗纤维板层型肝细胞癌：两例病例报告
J Med Case Rep. 2021 Mar 16;15(1):132. doi: 10.1186/s13256-021-02695-8.
4
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的患者报告结局（IMbrave150）：一项开放标签、随机、3期试验
Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.
5
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗对比索拉非尼用于不可切除或转移性肝细胞癌患者的成本效果分析。
JAMA Netw Open. 2021 Apr 1;4(4):e214846. doi: 10.1001/jamanetworkopen.2021.4846.
6
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗与索拉非尼作为不可切除肝细胞癌一线治疗的成本效果比较。
JAMA Netw Open. 2021 Feb 1;4(2):e210037. doi: 10.1001/jamanetworkopen.2021.0037.
7
Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝癌伴大血管癌栓的显著疗效：一例报告。
BMC Gastroenterol. 2021 Dec 15;21(1):470. doi: 10.1186/s12876-021-02053-4.
8
Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗在不可切除肝细胞癌序贯治疗中的作用。
Anticancer Res. 2022 Mar;42(3):1403-1412. doi: 10.21873/anticanres.15610.
9
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.阿替利珠单抗联合或不联合贝伐珠单抗治疗不可切除肝细胞癌（GO30140）：一项开放标签、多中心、1b 期研究。
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
10
Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice.阿替利珠单抗联合贝伐单抗用于晚期肝细胞癌临床实践的初步经验
Cancer Diagn Progn. 2021 May 3;1(2):83-88. doi: 10.21873/cdp.10012. eCollection 2021 May-Jun.
引用本文的文献
1
Extracellular vesicle-associated organotropic metastasis.细胞外囊泡相关的器官特异性转移。
Cell Prolif. 2021 Jan;54(1):e12948. doi: 10.1111/cpr.12948. Epub 2020 Nov 3.
本文引用的文献
1
Atezolizumab plus Bevacizumab - A Landmark in Liver Cancer.阿替利珠单抗联合贝伐单抗——肝癌治疗的一个里程碑。
N Engl J Med. 2020 May 14;382(20):1953-1955. doi: 10.1056/NEJMe2004851.
2
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
3
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
4
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南：肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
5
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
6
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.用于阿替利珠单抗的程序性死亡受体配体1（PD-L1）补充诊断免疫组织化学检测法（SP142）的研发
Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100. doi: 10.1097/PAI.0000000000000594.
7
Comparison of hepatocellular carcinoma in Eastern versus Western populations.东西方人群肝细胞癌的比较。
Cancer. 2016 Nov 15;122(22):3430-3446. doi: 10.1002/cncr.30237. Epub 2016 Sep 13.
8
Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study.再出血预防可改善肝细胞癌患者的预后。一项多中心病例对照研究。
Hepatology. 2013 Dec;58(6):2079-88. doi: 10.1002/hep.26629. Epub 2013 Oct 15.
9
Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma.肝细胞癌患者食管静脉曲张的患病率及其预后意义
Clin Gastroenterol Hepatol. 2006 Nov;4(11):1378-84. doi: 10.1016/j.cgh.2006.08.011. Epub 2006 Oct 23.
Zotero 插件